Mysulin 30/70 (100 IU-ml) penset

Mysulin 30/70 – Biphasic Human Insulin 100 IU/ml Penset

What is Mysulin 30/70 Penset?

Mysulin 30/70 is a premixed biphasic human insulin in a 3 ml penset (pen cartridge) format, manufactured by Popular Pharmaceuticals Ltd., Bangladesh. It contains 30% short-acting soluble human insulin and 70% intermediate-acting isophane (NPH) human insulin — delivering both rapid post-meal glucose control and sustained inter-meal basal coverage in a single twice-daily injection. The penset format is designed for use with compatible reusable insulin pen devices, offering an ergonomic, discreet alternative to syringe-based injection. Mysulin 30/70 is widely used in Bangladesh as a cost-effective, locally manufactured option for Type 2 diabetes management.

Generic Name and Composition

Each ml contains: 30 IU soluble human insulin + 70 IU isophane human insulin = 100 IU/ml. The soluble fraction provides rapid action (onset 30 min, peak 2–4 hrs) for post-meal glucose coverage. The isophane (NPH) fraction provides intermediate duration (peak 4–12 hrs, duration up to 24 hrs) bridging between meals and overnight. This dual-phase action profile is designed to mimic a simplified version of physiological insulin secretion.

Indications

• Type 2 diabetes mellitus requiring twice-daily premixed insulin therapy
• Patients initiating insulin who prefer pen delivery over syringes
• Patients transitioning from oral antidiabetics to insulin
• Type 2 patients unable to manage a separate basal-bolus regimen

How It Works — Mechanism of Action

After SC injection, the soluble fraction is absorbed rapidly, peaking at 2–4 hours and controlling post-breakfast or post-dinner glucose. The NPH fraction is slowly absorbed from its crystalline suspension — providing a broad intermediate peak at 4–12 hours that suppresses hepatic glucose production and controls fasting glucose. The combined twice-daily injection covers glucose across the full 24-hour cycle: morning dose covers breakfast and lunch; evening dose covers dinner and overnight.

Dosage and Administration

Inject 30 minutes before breakfast and dinner. Starting dose: 0.2–0.4 IU/kg/day split between morning and evening, adjusted by physician. Always roll the pen device 10 times before injecting to resuspend the NPH fraction. The suspension should appear uniformly milky white. Inject SC into abdomen, thigh, or upper arm — rotate injection sites to prevent lipohypertrophy.

Side Effects

Very common: Hypoglycaemia (especially if meal timing is irregular). Common: Injection site reactions, lipohypertrophy, weight gain. Uncommon: Lipoatrophy, peripheral oedema, visual changes at treatment initiation. Rare: Hypersensitivity reactions, anaphylaxis.

Drug Interactions

Enhance hypoglycaemia: Oral antidiabetics, GLP-1 agonists, SGLT-2 inhibitors, ACE inhibitors, salicylates, MAO inhibitors, alcohol. Reduce insulin effect: Corticosteroids, glucagon, thyroid hormones, sympathomimetics, thiazide diuretics, oral contraceptives. Mask hypoglycaemia symptoms: Beta-blockers, clonidine.

Contraindications

• Active hypoglycaemic episode
• Hypersensitivity to human insulin or excipients
• Intravenous use (penset is for SC injection only)

Pregnancy and Lactation

Pregnancy: Human insulin is the standard of care for diabetes in pregnancy; monitor closely. Lactation: No clinically significant passage into breast milk. Use as directed by physician.

Precautions and Warnings

• Resuspend before each injection — roll loaded pen 10 times. Do not use if suspension is not uniformly cloudy white.
• Do not miss or delay meals after injection — the soluble fraction peaks rapidly regardless of food intake.
• Do not freeze. Store in-use penset below 25 degrees C away from light.
• Sick days: Monitor glucose every 4 hours; consult physician for adjustment during febrile illness.

Overdose

Hypoglycaemia of variable severity. Mild: oral glucose or carbohydrate. Severe: IV dextrose 20–50% or IM glucagon 1 mg. Due to the NPH component, effects can persist 12–24 hours — extended monitoring and possible repeat glucose/glucagon administration may be needed.

Storage Instructions

• Unopened penset: 2–8 degrees C. Do not freeze.
• In-use penset: Below 25 degrees C. Protect from light and heat.
• Discard 28 days after first use.

Frequently Asked Questions

Q1: What does "penset" mean for Mysulin 30/70?
"Penset" refers to a 3 ml pen cartridge designed to be loaded into a compatible reusable insulin pen device. It is functionally identical to a pen cartridge — the term is used by some Bangladeshi manufacturers. When loaded into the pen device and the cartridge is empty, only the cartridge is replaced, not the pen itself. This reduces waste and ongoing cost compared to fully disposable pens.

Q2: Who manufactures Mysulin?
Mysulin is manufactured by Popular Pharmaceuticals Ltd., Bangladesh — one of the country's established pharmaceutical companies. The Mysulin range provides locally manufactured insulin options at accessible prices for Bangladeshi patients.

Q3: Is Mysulin 30/70 equivalent to Mixtard 30 HM or Humulin 30/70?
Yes — all three are 30% soluble + 70% NPH human insulin at 100 IU/ml. Clinical equivalence per unit is the same. Mysulin is manufactured locally in Bangladesh, making it more affordable and often more readily available than the imported brands.

Q4: Can Mysulin 30/70 be used for Type 1 diabetes?
It can be used in Type 1 diabetes in specific situations (e.g., twice-daily premix regimen), but most Type 1 patients require a basal-bolus regimen with individually titrated doses. Premixed insulins have limited dose flexibility. Consult your diabetologist to determine the most appropriate regimen.

Medical Disclaimer: For educational purposes only. Mysulin 30/70 is Rx-only. Consult your diabetologist before starting or changing insulin therapy. DiabetesStore.com.bd is a licensed online pharmacy in Bangladesh.